• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

A Drug To Treat Frostbite Is Finally Available

February 24, 2024 by Deborah Bloomfield

The ConversationFrostbite can occur at temperatures just below freezing (-0.55°C), though at such temperatures frostbite is typically mild and no permanent damage will result. But what happens if you live and work somewhere where it gets much colder?

As a Canadian, I am used to seeing news reports during cold snaps warning people to avoid going outdoors due to frostbite being possible “in under a minute”.

Advertisement

Until now, there have been no approved therapies for severe frostbite. But on February 14 2024, the US Food and Drug Administration (FDA) announced that it had approved the very first drug to treat frostbite.

Frostbite is evolution’s response to prolonged or extreme cold, causing blood vessels to constrict and blood flow to slow in the extremities. This keeps blood flowing in the vital organs warm, increasing the chance of surviving in the extreme cold.

The downside is this can result in permanent damage to the fingers, toes and parts of the face, sometimes requiring amputation of the affected body parts. (Frostbite has resulted in some odd traditions, such as the Sourtoe Cocktail in Dawson City where customers drink a cocktail containing an amputated frostbitten toe.)

Repurposed drug

The new drug, called iloprost (brand name Aurlumyn), is repurposed. This means that it was not originally developed to treat frostbite. In this case, it is used to treat high blood pressure within the lungs.

Advertisement

Repurposed drugs have already passed important (and expensive) human safety testing and are therefore much cheaper (about US$40-80 million or £32-64 million) to develop for additional medical issues versus creating a new drug (about US$1-2 billion), making drug repurposing an attractive way to find new treatments.

Many drugs have been tried as potential treatments for severe frostbite. However, iloprost is the first to be put through a clinical trial where patients with severe frostbite were randomly allocated to receive iloprost or not.

The study found that 60 percent of the patients who did not receive iloprost had injuries sufficiently severe to warrant amputation, versus 0 percent of the patients who received iloprost.

While the total number of patients tested in this study was small at 47, the combined facts that there are no other approved pharmaceutical treatments for frostbite and the impressive digit-saving results found in this randomised human trial were sufficient to convince the FDA to approve this repurposed therapy for severe frostbite.

How it works

Iloprost works by expanding the blood vessels (called a vasodilator) of patients and stopping blood clots from forming. As frostbite causes constriction of blood vessels, this suggests one mechanism through which iloprost helps heal frostbitten tissue is by reversing this constriction.

However, whenever blood flow is reintroduced in such tissue, it can paradoxically worsen the injury and cause more damage. This is called “reperfusion injury” and is largely caused by a sudden influx of oxygen causing oxidative stress. Interestingly, iloprost is not only a vasodilator but also reduces oxidative stress, suggesting this dual mechanism of action could help explain its impressive potential as a frostbite treatment.

Frostbite is a common condition in colder parts of the world with one Finnish study finding that 1.1 percent of the Finnish population experiences severe frostbite every year and 12.9 percent suffer from mild frostbite. As the injuries from frostbite can be serious, the approval of a drug that significantly reduces the risk of life-altering amputations of patients’ fingers, toes and noses will certainly be welcome news to many.

However, an unintended consequence may be that the Sourtoe Cocktail Club has a harder time finding new frostbitten toes to add to its collection in the coming years.

Advertisement

Steven R. Hall, Lecturer in Pharmacology, Lancaster University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Soccer – FIFA backs down on threat to fine Premier clubs who play South American players
  2. U.S. House passes abortion rights bill, outlook poor in Senate
  3. UBS clients raise $650 million for biggest yet biotech impact fund
  4. We’ve Breached Six Of The Nine “Planetary Boundaries” For Sustaining Human Civilization

Source Link: A Drug To Treat Frostbite Is Finally Available

Filed Under: News

Primary Sidebar

  • Surströmming: Why Sweden’s Stinky Fermented Fish Smells So Bad (But People Still Eat It)
  • First-Ever Recording Of Black Hole Recoil Captured During Merger – And You Can Listen To It
  • The Moon Is Moving Away From Earth At A Rate Of About 3.8 Centimeters Per Year. Will It Ever Drift Apart?
  • As Solar Storm Hits Earth NASA Finds “The Sun Is Slowly Waking Up”
  • Plate Tectonics And CO2 On Planets Suggest Alien Civilizations “Are Probably Pretty Rare”
  • How To Watch The “Awkward” Partial Solar Eclipse This Weekend
  • World’s Oldest Pots: 20,000-Year-Old Vessels May Have Been Used For Cooking Clams Or Brewing Beer
  • “The Body Is Slowly And Continuously Heated”: 14,000-Year-Old Smoked Mummies Are World’s Oldest
  • Pizza Slices, Polaroid Pictures, And Over 300 Hats: What’s Left Behind In Yellowstone’s Hydrothermal Areas?
  • The Mathematical Paradox That Lets You Create Something From Nothing
  • Ancient Asteroid Ripped Apart In Collision Had Flowing Water
  • Flying Foxes Include The World’s Biggest Bat And The Largest Mammal Capable Of True Flight
  • NASA Responds To Claims That Interstellar Object 3I/ATLAS Is An Advanced Alien Spacecraft
  • Millions Of Tons Of Gold Are In Earth’s Oceans, Potentially Worth Over $2 Quadrillion
  • The Race Back To The Moon: US Vs China, Will What Happens Next Change The Future?
  • NOAA Issues G3 Geomagnetic Storm Warning As 500,000 Kilometer Hole Sends Solar Wind At Earth
  • Lasting 776 Days, This Is The Longest Case Of COVID-19 Ever Recorded
  • Living Cement: The Microbes In Your Walls Could Power The Future
  • What Can Your Earwax Reveal About Your Health?
  • Ever Seen A Giraffe Use An Inhaler? Now You Can, And It’s Incredibly Wholesome
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version